NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum

Rhea-AI Summary

NewAmsterdam Pharma (NASDAQ:NAMS), a late-stage clinical biopharmaceutical company focused on developing oral, non-statin medicines for cardiovascular disease patients, has announced its participation in the Stifel 2025 Virtual Cardiometabolic Forum.

The company's Chief Scientific Officer, John Kastelein, and EVP of Investor Relations, Matthew Philippe, will engage in a virtual fireside chat on September 30, 2025, at 11:00 a.m. ET. Investors can access the live webcast through NewAmsterdam's investor relations website, with an archived replay available afterward.

NAARDEN, The Netherlands and MIAMI, Sept. 24, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that John Kastelein, Chief Scientific Officer, and Matthew Philippe, Executive Vice President, Head of Investor Relations, will participate in a virtual fireside chat at the Stifel 2025 Virtual Cardiometabolic Forum on Tuesday, September 30, 2025 at 11:00 a.m. ET.

A live webcast of the fireside chat will be available through the investor relations section of the NewAmsterdam Pharma website at ir.newamsterdampharma.com. Following the live webcast, an archived replay will be available on the Company’s website.

About NewAmsterdam

NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.

Company Contact
Matthew Philippe
P: 1-917-882-7512
matthew.philippe@newamsterdampharma.com

Media Contact
Real Chemistry on behalf of NewAmsterdam
Christian Edgington
P: 1-513-310-6410
cedgington@realchemistry.com

Investor Contact
Precision AQ on behalf of NewAmsterdam
Austin Murtagh
P: 1-212-698-8696
austin.murtagh@precisionaq.com

FAQ

When is NewAmsterdam Pharma (NAMS) presenting at the Stifel 2025 Virtual Cardiometabolic Forum?

NewAmsterdam Pharma will present at the forum on Tuesday, September 30, 2025 at 11:00 a.m. ET through a virtual fireside chat.

Who will be presenting for NewAmsterdam Pharma at the Stifel 2025 forum?

John Kastelein, Chief Scientific Officer, and Matthew Philippe, Executive Vice President and Head of Investor Relations, will participate in the fireside chat.

How can investors access NewAmsterdam Pharma's presentation at the Stifel forum?

Investors can access the live webcast through the investor relations section of NewAmsterdam's website at ir.newamsterdampharma.com. An archived replay will be available afterward.

What is NewAmsterdam Pharma's (NAMS) main focus in drug development?

NewAmsterdam Pharma focuses on developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated LDL-C, particularly for those whom existing therapies are not sufficiently effective or well-tolerated.